MOF/Hip Fracture Ratio in a Belgian Cohort of Post-menopausal Women (FRISBEE): Potential Impact on the FRAX® Score.


Journal

Calcified tissue international
ISSN: 1432-0827
Titre abrégé: Calcif Tissue Int
Pays: United States
ID NLM: 7905481

Informations de publication

Date de publication:
12 2021
Historique:
received: 29 03 2021
accepted: 08 06 2021
pubmed: 24 6 2021
medline: 30 10 2021
entrez: 23 6 2021
Statut: ppublish

Résumé

The ratio between major osteoporotic fractures (MOFs) and hip fractures in the Belgian FRAX® tool to predict fractures is currently based on Swedish data. We determined these ratios in a prospective cohort of Belgian postmenopausal women. 3560 women, aged 60-85 years (70.1 ± 6.4 years), were included in a prospective study from 2007 to 2013 and surveyed yearly (FRISBEE). We analyzed the number of validated incident fractures until October 2020 by age and sites and compared the MOFs/hip ratios in this cohort with those from the Swedish databases. We registered 1336 fractures (mean follow-up of 9.1 years). The MOFs/hip ratios extracted from the FRISBEE cohort were 10.7 [95% CI: (5.6-20.5)], 6.4 [4.7-8.7], and 5.0 [3.9-6.5] for women of 60-69, 70-79, and 80-89 years old, respectively. These ratios were 1.7-1.8 times higher for all age groups than those from the Swedish data, which decreased from 6.5 (60-64 years group) down to 1.8 (85-89 age group). The overall MOFs/hip ratio in Frisbee was 6.0 [5.9-6.1], which was higher than any Swedish ratio between 65 and 85 years. Nevertheless, the decrease of the ratios with age paralleled that observed in Sweden. In this Brussels prospective cohort, MOFs/hip ratios were 1.7-1.8 times those observed in Sweden currently used for MOFs prediction in the Belgian FRAX® version. This discrepancy can greatly modify the estimation of the risk of MOFs, which is among the main criteria used to recommend a pharmacological treatment for osteoporosis in several countries.

Identifiants

pubmed: 34159447
doi: 10.1007/s00223-021-00875-8
pii: 10.1007/s00223-021-00875-8
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

600-604

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Références

Kanis JA, Johansson H, Harvey NC, McCloskey EV (2019) A brief history of FRAX. Arch Osteoporos 13(1):118. https://doi.org/10.1007/s11657-018-0510-0
doi: 10.1007/s11657-018-0510-0
Kanis JA, Oden A, Johansson H, De Laet C, Brown J et al (2007) The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 18:1033–1046. https://doi.org/10.1007/s00198-007-0343-y
doi: 10.1007/s00198-007-0343-y pubmed: 17323110
Johansson H, Kanis JA, McCloskey OA et al (2011) A FRAX model for the assessment of fracture probability in Belgium. Osteoporos Int 22:453–461. https://doi.org/10.1007/s00198-010-1218-1
doi: 10.1007/s00198-010-1218-1 pubmed: 20352409
Kanis JA, Oden A, Johnell O, Jonsson B, De Laet C, Dawson A (2000) The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 12:417–427. https://doi.org/10.1007/s001980170112
doi: 10.1007/s001980170112
Kanis JA, Johnell O, Oden A, Sembo I, Redlund-Johnell I, Dawson A, De Laet C, Jonsson B (2000) Long-term risk of osteoporotic fracture in Malmö. Osteoporos Int 11(8):669–674. https://doi.org/10.1007/s001980070064
doi: 10.1007/s001980070064 pubmed: 11095169
Hiligsmann M, Bruyere O, Ethgen O, Gathon HJ, Reginster JY (2008) Lifetime absolute risk of hip and other osteoporotic fracture in Belgian women. Bone 43:991–994. https://doi.org/10.1016/j.bone.2008.08.119
doi: 10.1016/j.bone.2008.08.119 pubmed: 18817901
Cappelle SI, Ramon I, Dekelver C et al (2017) Distribution of clinical risk factors for fracture in a Brussels cohort of postmenopausal women: the FRISBEE study and comparison with other major cohort studies. Maturitas 106:1–7. https://doi.org/10.1016/j.maturitas.2017.08.010
doi: 10.1016/j.maturitas.2017.08.010 pubmed: 29150162
Baleanu F, Moreau M, Kinnard V, Iconaru L, Karmali R, Paesmans M, Bergmann P, Body JJ (2020) What is the validity of self-reported fractures? Bone Rep 12:100256. https://doi.org/10.1016/j.bonr.2020.100256
doi: 10.1016/j.bonr.2020.100256 pubmed: 32382588 pmcid: 7200867
Baleanu F, Moreau M, Kinnard V, Iconaru L, Karmali R, Rozenberg S, Rubinstein M, Paesmans M, Bergmann P, Body JJ (2020) Underevaluation of fractures by self-report: an analysis from the FRISBEE cohort. Arch Osteoporos 15(1):61. https://doi.org/10.1007/s11657-020-00739-y
doi: 10.1007/s11657-020-00739-y pubmed: 32323006
Iconaru L, Moreau M, Kinnard V, Baleanu F, Paesmans M, Karmali R, Body JJ, Bergmann P (2019) Does the prediction accuracy of osteoporotic fractures by BMD and clinical risk factors vary with fracture site? JBMR Plus 3(12):e10238. https://doi.org/10.1002/jbm4.10238
doi: 10.1002/jbm4.10238 pubmed: 31844826 pmcid: 6894722
Sullivan L (2018) Essentials of Biostatistics in Public Health. 3rd edition. Chapter 6.
Lam A, Leslie WD, Lix LM, Yogendran M, Morin SN, Majumdar SR (2014) Major osteoporotic to hip fracture ratios in Canadian men and women with Swedish comparisons: a population-based analysis. J Bone Miner Res 29(5):1067–73. https://doi.org/10.1002/jbmr.2146
doi: 10.1002/jbmr.2146 pubmed: 24243719
Jiang X et al (2017) Diagnostic accuracy of FRAX in predicting the 10-year risk of osteoporotic fractures using the USA treatment thresholds: a systematic review and meta-analysis. Bone 99:20–25. https://doi.org/10.1016/j.bone.2017.02.008
doi: 10.1016/j.bone.2017.02.008 pubmed: 28274799
Sornay-Rendu E, Munoz F, Delmas PD, Chapurlat RD (2010) The FRAX tool in French women: how well does it describe the real incidence of fracture in the OFELY cohort? J Bone Miner Res 25:2101–2107
doi: 10.1002/jbmr.106
Tuzun S, Eskiyurt N, Akarırmak U, Sarıdoğan M, Şenocak M, Johansson H, Kanis JA, Turkish Osteoporosis Society (2012) Incidence of hip fracture and prevalence of osteoporosis in Turkey: the FRACTURK study. Osteoporos Int 23(3):949–955. https://doi.org/10.1007/s00198-011-1655-5
doi: 10.1007/s00198-011-1655-5 pubmed: 21594756
Piscitelli P, Chitano G, Johannson H, Brandi ML, Kanis JA, Black DM (2013) Updated fracture incidence rates for the Italian version of FRAX(R). Osteoporos Int 24:859–866. https://doi.org/10.1007/s00198-012-2021-y
doi: 10.1007/s00198-012-2021-y pubmed: 22638710
Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster J-Y, Scientific Advisory Board of the European Society for Clinical Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO), Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF) (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 24:23–57. https://doi.org/10.1007/s00198-012-2074-y
doi: 10.1007/s00198-012-2074-y pubmed: 23079689
Hiligsmann M, Bruyère O, Roberfroid D, Dubois C, Parmentier Y, Carton J, Detilleux J, Gillet P, Reginster JY (2012) Trends in hip fracture incidence and in the prescription of antiosteoporosis medications during the same time period in Belgium (2000–2007). Arthritis Care Res 64(5):744–50. https://doi.org/10.1002/acr.21607
doi: 10.1002/acr.21607

Auteurs

A Mugisha (A)

Department of Geriatrics, CHU Brugmann, Université Libre de Bruxelles, Place van Gehuchten 4 Laeken, 1020, Brussels, Belgium. aude.ndamama@gmail.com.

P Bergmann (P)

Department of Nuclear Medicine, CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium.
Laboratory of Translational Medicine, CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium.

V Kinnard (V)

Department of Nuclear Medicine, CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium.

L Iconaru (L)

Department of Endocrinology, CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium.

F Baleanu (F)

Department of Endocrinology, CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium.

A Charles (A)

Department of Internal Medicine, CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium.

M Surquin (M)

Department of Geriatrics, CHU Brugmann, Université Libre de Bruxelles, Place van Gehuchten 4 Laeken, 1020, Brussels, Belgium.
Department of Internal Medicine, CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium.

S Rozenberg (S)

Department of Gynaecology-Obstetrics, CHU Saint-Pierre, Université Libre de Bruxelles, Brussels, Belgium.

F Benoit (F)

Department of Geriatrics, CHU Brugmann, Université Libre de Bruxelles, Place van Gehuchten 4 Laeken, 1020, Brussels, Belgium.

J J Body (JJ)

Laboratory of Translational Medicine, CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium.
Department of Endocrinology, CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium.
Department of Internal Medicine, CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH